Clinical trials
Observational Retinopathy of Prematurity trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 2 |
| 2016 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 33 |
| Unknown status | 8 |
| Recruiting | 7 |
| Terminated | 3 |
| Not yet recruiting | 3 |
| Withdrawn | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chang Gung Memorial Hospital | 3 |
| Ameera Gamal Abdelhameed | 2 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Bayer | 2 |
| Children's Hospital of Philadelphia | 2 |
| Duke University | 2 |
| Novartis Pharmaceuticals | 2 |
| Alaska Blind Child Discovery | 1 |
| Ankara City Hospital Bilkent | 1 |
| Assiut University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Retinopathy of Prematurity | 59 |
| Premature Birth | 14 |
| Bronchopulmonary Dysplasia | 5 |
| Retinal Diseases | 4 |
| Birth Weight | 2 |
| Hyperoxia | 2 |
| Macular Edema | 2 |
| Myopia | 2 |
| Neurodevelopmental Disorders | 2 |
| Refractive Errors | 2 |
Trials
Showing 51 to 59 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.